Abstract: Objective 　Chk1/ 2 (checkpoint kinase 1/ 2) and Plk1 (polo2like kinase 1) play the major role in cell cycle checkpoint block when DNA lesion are emerged, this study was to investigate the expression of these kinases in endomet rial carcinoma and healthy endomet ria, and to explore their relationships with clinical pathology parameters of endomet rial carcinoma and the correlations among three kinases. Methods 　Immunohistochemist ry was applied to detect the expressions of Chk1, Chk2 and Plk1 in 44 cases of en2 domet rial carcinoma and 21 cases of healthy endomet ria. Results 　The positive percentages of Chk1, Chk2 and Plk1 were 47. 7 %、75. 0 % and 31. 8 % respectively in endomet rial carcinoma, and were 61. 9 %、61. 9 % and 4. 8 % respectively in healthy endomet ria ; The expression of plk1 proteins in endomet rial car2 cinoma was higher than that in healthy endomet ria, and the difference of plk1 was significant ( P < 0. 01), while the expression differences of Chk1 and chk2 were no significant ( P > 0. 05) . The expressions of Chk1, Chk2 and Plk1 were not associated with the age, pathology and clinical stage of endomet rial carci2 noma patient s ( P > 0. 05), while Chk1 expressions associated with differentiation of endomet rial carcino2 ma ( P < 0. 05) . In 44 endomet rial carcinoma cases, Chk2 was positively correlated with plk1 ( r = 0. 482, P = 0. 001) . Conclusion 　Plk1 might be ideal target s for endomet rial carcinoma therapy, while the expres2 sions and significances of CHK1/ 2 in endomet rial carcinoma need further research.